Upload
benito
View
40
Download
1
Tags:
Embed Size (px)
DESCRIPTION
Pharmaceuticals Limited. India – CIS International Pharma Conference 3-5 th March 2006, Mumbai. Prashant Nagre Vice President – API Division. Top 10 destinations for Formulations Russia ranks 2nd. Top 10 destinations for Bulk Drugs Russia and CIS does not feature !. - PowerPoint PPT Presentation
Citation preview
Pharmaceuticals LimitedPharmaceuticals Limited
India – CIS International Pharma ConferenceIndia – CIS International Pharma Conference3-53-5thth March 2006, Mumbai March 2006, Mumbai
Prashant NagreVice President – API Division
Top 10 destinations for Top 10 destinations for Bulk DrugsBulk DrugsRussia and CIS does not feature !Russia and CIS does not feature !
Top 10 destinations for Top 10 destinations for FormulationsFormulations Russia ranks Russia ranks 2nd2nd
What should be our OBJECTIVE?
CIS should be among CIS should be among
TOP 5TOP 5 destinationsdestinations
IndianIndian PharmaceuticalPharmaceutical IndustryIndustry
An OverviewAn Overview
Industry Overview - More than 8,000 to 9,000 manufacturing units 300 Large and Medium sized companies account for more
than 80% turnover Performance
Turnover : $ 8.2 bn, growth 9% Exports : $ 3.5 bn, growth 14.86% API exports contribute 32%, growth 5%
Well established central & regional network of Regulatory authorities
Patent Act of 1970 helped the industry to grow rapidlyINDIA IS SELF-SUFFICIENT TODAY
Industry Overview Infrastructure
Well developed, most of the pharmaceutical machinery locally made, Engineering and plant designs matching international standards
cGMP compliant manufacturing infrastructure International approvals/accreditations
US FDA approvals - >80 units UK MHRA TGA, Australia WHO-GMP
Talent Pool Availability of educated manpower in abundance (Pharmacy,
Engineering, Biotech and Science graduates) Rich scientific talent & research capabilities
Strengths : Strengths :
Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients IndustryIndustry
Strengths – Bulk Drug IndustryReverse Engineering –
Process patents regime helped Indian industry to gain significant skills in Chemistry and process engineering
Quality – comparable to best in world
Competitiveness – Through efficiencies and lower cost of production in India
Understanding of regulatory requirements – More than 35% of DMFs were filed from India in the US
State-of-the-art R&D infrastructure
Strengths – Bulk Drug Industry
Introduction of product patents Ability to be a partner in outsourcing and launch
of new products
Product Portfolio wide variety of drugs substances produced
(Traditional antibiotics, New lifestyle categories like Cardiac, Respiratory and Vitamins, Anti HIV/ AIDS, CNS & Diabetic )
Bird flu : Indian companies in the fore front
Major Players : Bulk Drug Industry
• Ranbaxy Labs
• Cipla
• Dr Reddy Labs
• GSK
• Nicholas Piramal
• Lupin Ltd
• Sun Pharma
• Cadila Healthcare
• Aurobindo Pharma
• Wockhardt Ltd
(Source: Compiled by Cygnus)
Why to buy Why to buy Indian Pharmaceuticals ?Indian Pharmaceuticals ?
Why to buy Why to buy Indian Pharmaceuticals ?Indian Pharmaceuticals ?
Reliability
Growth in exports mainly attributable to this reason
Why to buy Why to buy Indian Pharmaceuticals ?Indian Pharmaceuticals ?
Consolidated know-how in production process
High Product Quality New regulatory compliance culture
Consistency in Quality Strict Regulatory Compliance
Products meet most stringent GMP standards Continuous technological innovation through
R & D Professionalism of sales and technical staff –
“Global Service”
Major Therapeutic Segments - 2004
Others4%
Gynaecologicals5%
CNS5%
Dermatologicals6%
Vitamins10%Analgesics
10%
Respiratory10%
Gastrointestinal11%
Cardiac11%
Anti-infectives16%
Opthalmologicals2%
Anti-diabetics5%
Hormones2%
Anti-TB2%Sex-Stimulants
1%
Top Bulk drug export destinations to CIS
Russia54%Ukraine
23%
Kyrgyzstan0%
Belarus10%
Uzbekistan3%
Kazakhstan2%
Turkmenistan2%
Moldova2%
Armenia2%
Tajikistan0%
Georgia1%
Azerbaijan1%
Top 10 bulk drugs exported to CIS countries
Ampicillin & its Salts33%
Diloxanide Furoate13%
Cefadroxil12%
Rifampicin10%
Ranitidine9%
Metronidazole/Metro Benzoate
5%
HCl5%
Amoxycilling & its salts,Ethambutal, Ethambutol HCL
5%
Cephalexin & its salts4% Ciprofloxacin & its sales
4%
Opportunities ex-IndiaOpportunities ex-India
Opportunities Exports
Bulk Drugs Chemicals/Raw materials/Intermediates Biotech & Biological Products
Joint Ventures with Indian Companies Technology acquisitions
Opportunities Pellets/Directly compressible granules/times
release products Contract Research and Manufacturing
(CRAMS) Diversification in Destination –
Russia & Ukraine constituted 78% of total bulk drug exports
Vision for Indian Pharmaceutical Industry
Padmabhushan Padmabhushan
Dr R A MashelkarDr R A Mashelkar
Be Innovative Not embark on beaten paths but traverse
untrodden paths
Have Compassion By creating therapeutics for poor that are
available, affordable and accessible
Have Passion To be best in the WORLD in terms of Quality of
products, highest ethical standards and providing value for money
Thank you.Thank you.